Garnet Equity Capital Holdings’s Krystal Biotech KRYS Stock Holding History

Garnet Equity Capital Holdings’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,000	Closed	-$1.2M	–	38
2020 Q4	$1.2M	Sell	20,000 -20,000	-50%	-$999K	0.35%	31
2020 Q3	$1.72M	Hold	40,000	–	–	0.35%	24
2020 Q2	$1.66M	Buy	+40,000	New	+$1.92M	0.33%	24
2020 Q1	–	Sell	-12,000	Closed	-$665K	–	22
2019 Q4	$665K	Sell	12,000 -16,000	-57%	-$785K	0.24%	21
2019 Q3	$972K	Sell	28,000 -17,000	-38%	-$760K	0.62%	18
2019 Q2	$1.81M	Buy	+45,000	New	+$1.47M	2.36%	17

Other funds holding KRYS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Garnet Equity Capital Holdings's KRYS Position: Q1 2021 in Review

Garnet Equity Capital Holdings sold out of Krystal Biotech (KRYS) in Q1 2021, closing a stake of 20,000 shares — an estimated $1.2M sold.

Garnet Equity Capital Holdings first reported a position in KRYS in Q2 2019 and held it in 6 quarters. The position peaked at $1.81M in Q2 2019. 113 funds tracked by Wall St. Rank hold KRYS as of Q1 2021.

Garnet Equity Capital Holdings reported no remaining Krystal Biotech position as of Q1 2021 after selling out during the quarter.
Garnet Equity Capital Holdings sold 20,000 Krystal Biotech shares in Q1 2021, an estimated $1.2M.
Garnet Equity Capital Holdings first reported a position in Krystal Biotech in Q2 2019 and held it in 6 quarters.
Garnet Equity Capital Holdings's Krystal Biotech position peaked at $1.81M in Q2 2019.
113 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2021.

Based on Garnet Equity Capital Holdings's 13F filing for Q1 2021, filed 26 Apr 2021.